Steven J. Cohen, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, explains the patient type and setting where Zelboraf (vemurafenib) has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Steven J. Cohen, MD, provides insight into sequencing and efficacy outcomes in 2nd line mCRC
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, compares sequencing Stivarga (regorafenib) followed by Erbitux (cetuximab) with the reverse sequence in terms of efficacy outcomes in 2nd line metastatic colorectal cancer (mCRC) patients
Steven J. Cohen, MD, describes how tumor sidedness impacts treatment decisions in mCRC
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, tells us how tumor sidedness affects treatment decisions in metastatic colorectal cancer (mCRC)
Steven J. Cohen, MD, regarding combination atezolizumab + cobimetinib in mCRC patients
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, elaborates on whether the combination of Tecentriq (atezolizumab) and Cotellic (cobimetinib) is effective in treatment of metastatic colorectal cancer (mCRC) patients
Steven J. Cohen, MD, considers the improvement in duration of therapy examined in the ReDOS study
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, discusses the importance of the improvement in duration of therapy as examined in the ReDOS study
Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, explains how to consider dosing patients receiving Stivarga (regorafenib) as a result of the ReDOS study
Michael Soulen, MD, discusses the most compelling presentations from ASCO GI 2018
Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, offers his opinion on the most compelling data coming out of ASCO GI 2018
Michael Soulen, MD, compares the possible benefits of retrospective vs. prospective trials
Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, considers the benefits of retrospective versus prospective trials in resectable and unresectable metastatic neuroendocrine tumors
Michael Soulen, MD, on the practice changing potential of data presented at his ASCO GI tumor board
Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, elaborates on how data presented at his ASCO GI tumor board session has the potential to be practice changing
Michael Soulen, MD, tells us about significant data coming out of the tumor board at ASCO GI 2018
Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, shares significant data and conclusions from his ASCO GI 2018 tumor board
Philip Philip, MD, PhD, FRCP, discusses the impact of the Checkmate 142 study on mCRC
Dr. Philip, Professor of Medicine, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, discusses the importance of the Checkmate 142 study (ipilimumab + nivolumab) for metastatic colorectal cancer (mCRC) and how it may impact future therapies
Philip Philip, MD, PhD, FRCP, on the implications of the LAPACT study presented at ASCO 2018
Dr. Philip, Professor of Medicine, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, offers opinion on the results of the LAPACT study and whether adding nab-paclitaxel to gemcitabine improves efficacy for locally advanced pancreatic cancer patients
Philip Philip, MD, PhD, FRCP, considers the impact of immunotherapy agents in pancreatic cancer
Dr. Philip, Professor of Medicine, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, discusses the role of immunotherapy agents in pancreatic cancer and whether they have an impact on treatment outcome
Philip Philip, MD, PhD, FRCP, regarding key unmet needs in pancreatic ductal adenocarcinoma
Dr. Philip, Professor of Medicine, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, elaborates on the key unmet needs in treating pancreatic ductal adenocarcinoma
Nevena Damjanov, MD, shares the latest news in systemic therapy for advanced HCC at ASCO 2018
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, tells us about the exciting news in systemic therapy for advanced hepatocellular carcinoma (HCC) coming out of ASCO GI 2018
Nevena Damjanov, MD, on the use of pembrolizumab in HCC patients previously treated with sorafenib
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, offers opinion on whether Keytruda (pembrolizumab) is effective in hepatocellular carcinoma (HCC) patients that have been previously treated with Nexavar (sorafenib)
Nevena Damjanov, MD, outlines the role of TACE with systemic therapy in HCC patients
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, explains the role of TACE with systemic therapy in hepatocellular carcinoma (HCC) patients
David Ilson, MD, PhD, considers how to assess response in gastroesophageal cancer patients
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, elaborates on how to assess response in gastroesophageal cancer patients
Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, regarding the ReDOS study and whether, as a result, physicians are more likely to use Stivarga (regorafenib) and dose escalate for hepatocellular carcinoma (HCC) patients & metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, on whether adding binimetinib to immunotherapies improves overall response rates in metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses whether molecular profile matching improves outcomes in clinical trials with metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, elaborates on the outcomes of the BEACON Phase 3 study investigating the triple combination of encorafenib, binimetinib, and cetuximab in BRAF-mutant metastatic colorectal cancer (mCRC) patients and how this compares to prior data
Jeffrey Meyerhardt, MD, MPH, on dose escalation of regorafenib as a result of the ReDOS study
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, on the results of the ReDOS study and whether, as a result, physicians should feel comfortable using dose escalation of Stivarga (regorafenib)
Jeffrey Meyerhardt, MD, MPH, discusses the length of adjuvant therapy for colorectal cancer patients
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, analyzes whether three months of adjuvant therapy is enough for colorectal cancer (CRC) patients
Jeffrey Meyerhardt, MD, MPH, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, elaborates on the outcomes of the BEACON Phase 3 study investigating the triple combination of encorafenib, binimetinib, and cetuximab in BRAF-mutant metastatic colorectal cancer (mCRC) patients
Jeffrey Meyerhardt, MD, MPH, considers the addition of vemurafenib to the NCCN guidelines for mCRC
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, explains the patient type and setting where Zelboraf (vemurafenib) has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Nevena Damjanov, MD, discusses current treatment options and sequencing TKIs in HCC
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, provides insight into what physicians should know about current treatment options and sequencing TKIs in hepatocellular carcinoma (HCC) patients
Nevena Damjanov, MD, considers the shortcomings of RECIST in measuring efficacy in HCC patients
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, elaborates on the shortcomings of RECIST in measuring efficacy in hepatocellular carcinoma (HCC ) patients
Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, shares how Opdivo (nivolumab) is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms
Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, outlines the results of the Checkmate 142 study looking at Yervoy (ipilimumab) and Opdivo (nivolumab) in metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, considers the addition of vemurafenib to the NCCN guidelines for mCRC
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the patient type and setting where Zelboraf (vemurafenib) has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, analyzes the incidence of BRAF mutation in colorectal cancer (CRC) patients and what this means for treatment outcomes
Richard Kim, MD, offers analysis of the RAINFALL study in metastatic gastric & GE junction cancer
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses the RAINFALL study results in metastatic gastric and GE junction cancer patients and the implications for physicians
Richard Kim, MD, discusses pembrolizumab as an effective agent in HCC management
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, elaborates on Keytruda (pembrolizumab) as an agnet in the management of hepatocellular carcinoma (HCC) patients
Richard Kim, MD, considers the effectiveness of combination sorafenib and TACE in HCC patients
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, on whether it is effective to combine Nexavar (sorafenib) with TACE in hepatocellular carcinoma (HCC) patients
Richard Kim, MD, on the use and sequencing of TKIs in hepatocellular carcinoma (HCC)
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, describes how TKIs should be used in 1st line hepatocellular carcinoma (HCC) and how TKIs should be sequenced for the disease at this time
David Ilson, MD, PhD, discusses what can be done to improve outcomes in esophageal adenocarcinoma
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, on what can be done to improve outcomes in esophageal adenocarcinoma patients
David Ilson, MD, PhD, examines the results of the RAINFALL study at ASCO GI 2018
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, tells us about the results of the RAINFALL study in 1st line metastatic gastric or GE junction cancer patients
David Ilson, MD, PhD, on strategies for managing gastroesophageal patients after neoadjuvant therapy
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, outlines strategies for managing gastroesophageal patients who have had a complete response after neoadjuvant therapy
David Ilson, MD, PhD, on how we can individualize treatment of gastroesophageal cancer patients
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, offers opinion on how management of gastroesophageal cancer patients can be individualized
Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, tells us about the results of the Checkmate 142 study comparing Yervoy (ipilimumab) + Opdivo (nivolumab) compared to Yervoy (ipilimumab) alone in metastatic colorectcal (mCRC) patients
Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, on whether patient age impacts the reliability of the OncotypeDX recurrence score in colorectal cancer (CRC) patients
Andrew Zhu, MD, PhD, on the effectiveness of pembrolizumab in HCC patients treated with sorafenib
Dr. Zhu, Professor of Medicine, Harvard Medical School, Director, Liver Cancer Research, considers whether Keytruda (pembrolizumab) is effective in hepatocellular carcinoma (HCC) patients who have been previously treated with Nexavar (sorafenib)
Andrew Zhu, MD, PhD, shares thoughts on treating adjuvant hepatocellular carcinoma (HCC) today
Dr. Zhu, Professor of Medicine, Harvard Medical School, Director, Liver Cancer Research, elaborates on how to treat adjuvant hepatocellular carcinoma (HCC) today
Laura Dawson, MD, FRCPC, on additional randomized studies of external beam radiation
Dr. Dawson, Professor, Department of Radiation Oncology, University of Toronto, outlines additional randomized studies of external beam radiation
Laura Dawson, MD, FRCPC, tells us about the results of the START study
Dr. Dawson, Professor, Department of Radiation Oncology, University of Toronto, shares the results of the START study comparing transarterial chemoembolization plus external beam radiotherapy to Nexavar (sorafenib)
Laura Dawson, MD, FRCPC, discusses the design of the START study in HCC
Dr. Dawson, Professor, Department of Radiation Oncology, University of Toronto, elaborates on the design of the START study in hepatocellular carcinoma (HCC)
Laura Dawson, MD, FRCPC, provides some background on hepatocellular carcinoma (HCC)
Dr. Dawson, Professor, Department of Radiation Oncology, University of Toronto, on hepatocellular carcinoma (HCC) and why this patient population is particularly challenging to treat
Alan Venook, MD, outlines the role of liquid biopsy in gastrointestinal cancers
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, discusses the role of liquid biopsy in gastrointestinal cancers
Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, describes how immunotherapy is being integrated into colorectal cancer (CRC) treatment algorithms
Alan Venook, MD, on the impact of dose escalation of regorafenib in mCRC patients
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, explains how dose escalation of Stivarga (regorafenib) in metastatic colorectal cancer (mCRC) patients impacts efficacy and tolerability
Alan Venook, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, on the patient type and setting where Zelboraf (vemurafenib) has been added to the NCNN guidelines for metastatic colorectal cancer (mCRC) patients
Alan Venook, MD, explains how tumor sidedness affects therapeutic choice
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, describes how tumor sidedness impacts therapeutic choice
Khaldoun Almhanna, MD, MPH, offers opinion on the best way to manage early gastric cancer
Dr. Almhanna, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, considers the best way(s) to manage early gastric cancer
Khaldoun Almhanna, MD, MPH, discusses the risk factors to watch for gastroesophageal cancer
Dr. Almhanna, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, elaborates on some of the risk factors for gastroesophageal cancer that physicians should be on the lookout for
Kenneth Wang, MD, offers opinion on approaches to treating esophageal cancer
Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, tells us what approach or approaches to treating esophageal cancer might deliver the best outcomes in the future
Kenneth Wang, MD, on managing esophageal cancer patients who have completed neoadjuvant therapy
Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, describes how he manages esophageal cancer patients that have had a complete response to neoadjuvant therapy
Kenneth Wang, MD, on how to assess response in esophageal cancer and utilize the information
Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, offers opinion on the best way to assess response in esophageal cancer and what should be done with the information
Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, shares thoughts on how tumor sidedness affects therapeutic choice in metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, considers the ReDOS study and how 20% of patients remained on Stivarga (regorafenib) for 6+ months
Andrew Zhu, MD, PhD, shares the latest in systemic therapy for advanced HCC at ASCO GI 2018
Dr. Zhu, Professor of Medicine, Harvard Medical School, Director, Liver Cancer Research, elaborates on the latest in systemic therapy for advanced hepatocellular carcinoma (HCC) at ASCO GI 2018
Andrew Zhu, MD, PhD, on how we diagnose and assess response in HCC patients
Dr. Zhu, Professor of Medicine, Harvard Medical School, Director, Liver Cancer Research, explains how we diagnose and assess response in hepatocellular carcinoma (HCC) patients
Khaldoun Almhanna, MD, MPH, on surveillance and the management of gastroesophageal cancer
Dr. Almhanna, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, describes how surveillance is impacting the management of gastroesophageal cancer
Kenneth Wang, MD, considers how staging esophageal cancer has changed and improved
Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, explains how staging esophageal cancer has changed and improved over time
Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, discusses the outcomes of the ReDOS study and whether physicians should feel comfortable using dose escalation of Stivarga (regorafenib) in their practice
Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib
Dr. Meyerhardt, Clinical Director, Gastrointestinal Cancer Center, Associate Professor of Medicine, Harvard Medical School, on adopting vemurafenib in BRAF+ mutation metastatic CRC
Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients
Dr. Meyerhardt, Clinical Director, Gastrointestinal Cancer Center, Associate Professor of Medicine, Harvard Medical School, discusses the optimal duration of therapy in stage III colon cancer
Howard Hochster, MD, discusses the optimal duration of FOLFOX therapy in stage III colon cancer
Dr. Hochster, Associate Director for Clinical Services, Yale Cancer Center, on whether stage III colon cancer patients should be treated with 3 months of 6 months of FOLFOX therapy
Howard Hochster, MD, on the impact of SWOG 1406 in treating BRAF mutation positive CRC patients
Dr. Hochster, Associate Director for Clinical Services, Yale Cancer Center, describes his approach to treating BRAF mutation positive CRC patients as a result of the recent SWOG 1406 study
Richard Goldberg, MD, FASCO, regarding the optimal duration of therapy in stage III colon cancer
Dr. Goldberg, Medical Director, West Virginia University Cancer Institute, discusses the optimal duration of therapy in a stage III colon cancer patient
Richard Goldberg, MD, FASCO, defines “high-risk” and “low-risk” stage III colon cancer patients
Dr. Goldberg, Medical Director, West Virginia University Cancer Institute, differentiates between “high-risk” and “low-risk” in a stage III colon cancer patient
Leonard Saltz, MD, reflects on intriguing CRC clinical data presented at ASCO 2017
Dr. Saltz, Chief, Gastrointestinal Oncology Service, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, describes the most interesting clinical data related to CRC presented at ASCO 2017
Leonard Saltz, MD, offers opinion on the optimal duration of adjuvant chemotherapy in colon cancer
Dr. Saltz, Chief, Gastrointestinal Oncology Service, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the role and duration of adjuvant chemotherapy in colon cancer treatment
Philip Philip, MD, on what we’ve learned about the duration of therapy in the adjuvant CRC setting
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, elaborates on what we know about duration of therapy in the adjuvant CRC setting
